GOLDEN, Colo., Dec. 3 /PRNewswire/ -- CeMines(TM) Inc., a life sciences company specializing in molecular research and development of minimally invasive clinical diagnostic tests and targeted therapeutics for cancer, today announced the creation of its newest operating division: CeMines International Inc., a wholly owned subsidiary of CeMines, Incorporated. The Company also announced that Dr. Kaia Palm, Ph.D., is returning to CeMines as Executive Director of Clinical Development, CeMines International-Europe, Tallin, Estonia.
In 2000, Dr. Palm, along with Toomas Neuman, Ph.D., CeMines' CSO, directed vital cancer research and differentiated processes. Their ideas were integral to early accomplishments, including development of novel intellectual property and protocols for CeMines Molecular FingerPrinting(TM), a patent-pending bioinformatics process for identification and profiling of multiple cancer types.
"A comprehensive International business strategy is central to long-term competitive advantages," said Roger Attick, CEO of CeMines. "Estonia is a perfect location to expand our research-and-development initiatives, establish a regulatory-affairs presence in the European Union and accelerate commercialization of new methods and technology. CeMines will also leverage its presence in Europe to cultivate new research partnerships and distribution channels.
"Regarding Dr. Palm, I am very pleased she chose to return to CeMines-This is an epic event for the company," said Mr. Attick. "Dr. Palm is a highly respected cancer researcher in Scandinavia and northern Europe. More importantly, Kaia has been instrumental in supporting research for the Company's recent advancements in splice-variant diagnostic applications. Dr. Palm has worked behind the scenes optimizing novel protocols for breast and GI cancer diagnostics. Kaia has been an integral part of CeMines' corporate DNA since 2000. I am proud she is back on this team," said Mr. Attick.
Toomas Neuman, Ph.D., President of CeMines Diagnostics & Therapeutics Division and the Company's CSO, added: "Assessing our future clinical products and knowing Dr. Palm will be responsible for related initiatives in Europe is extremely encouraging. We are nearing completion of very important clinical testing. Having Kaia back on the team will ensure CeMines maintains clear competitive advantages."
Dr. Palm earned her Doctor of Medical Sciences (Ph.D.) degree in Molecular Neurobiology from The Karolinska Institute, Stockholm, Sweden. Dr. Palm is a 1987 graduate of Tartu University, Estonia, where she graduated cum laude with multiple majors in Physics, Chemistry and subsequent graduate honors in molecular biology and bioorganic chemistry. Her post-doctoral research was performed in Adelaide, Australia; Ft. Collins, Colo.; Helsinki, Finland; and Stockholm.
CeMines(TM) Inc., a life sciences company specializing in molecular research, is developing minimally invasive clinical diagnostic tests and targeted therapeutics for cancer. CeMines' novel approach to understanding human cellular regulatory mechanisms resulted in the discovery of CeMines Molecular FingerPrinting(TM), a patent-pending bioinformatics process for identification of and profiling cancer cells. CeMines' headquarters is in Golden, Colorado: http://www.cemines.com/.
Ronald Trahan, APR
Ronald Trahan Associates, Inc.